Country: Canada
Language: English
Source: Health Canada
ALFENTANIL (ALFENTANIL HYDROCHLORIDE)
SANDOZ CANADA INCORPORATED
N01AH02
ALFENTANIL
500MCG
SOLUTION
ALFENTANIL (ALFENTANIL HYDROCHLORIDE) 500MCG
INTRAVENOUS
2ML*10
Narcotic (CDSA I)
OPIATE AGONISTS
Active ingredient group (AIG) number: 0119704002; AHFS:
CANCELLED POST MARKET
2019-08-01
_Alfentanil Injection USP _ _Page 1 of 36_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION N ALFENTANIL INJECTION USP Alfentanil Hydrochloride Solution for Injection, 500 mcg/mL, Intravenous USP Opioid Analgesic Adjunct to Anesthesia Sandoz Canada Inc. 145 Jules-Léger Boucherville, QC, Canada J4B 7K8 Date of Revision: March 8, 2018 Submission Control No: 204960 _ _ _Alfentanil Injection USP _ _Page 2 of 36_ RECENT MAJOR LABEL CHANGES Transfer into new template Dec, 2018 Include information for Opioid Class Labelling Dec, 2018 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 3 1 INDICATIONS ................................................................................................................... 3 1.1 Pediatrics ................................................................................................................. 3 1.2 Geriatrics ................................................................................................................. 3 2 CONTRAINDICATIONS ................................................................................................... 3 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................ 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.1 Dosing Considerations ............................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment ....................................................... 6 4.3 Administration .......................................................................................................... 9 5 OVERDOSAGE ................................................................................................................ 9 6 DOSAGE FORMS, STRENGTHS, COMPOSITION A Read the complete document